Eliglustat (Cerdelga®)

Assessment Status Assessment process complete
Drug Eliglustat
Brand Cerdelga®
Indication For the long-term treatment of adult patients with Gaucher disease type 1.
Assessment Process
Rapid review commissioned 21/03/2016
Rapid review completed 17/05/2016
Rapid review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE 31/05/2016
Pre-submission consultation with Applicant 27/09/2016
Full submission received from Applicant 09/05/2017
Preliminary review sent to Applicant 07/09/2017
NCPE assessment re-commenced 20/10/2017
Factual accuracy sent to Applicant 27/02/2018
NCPE assessment re-commenced 09/03/2018
NCPE assessment completed 25/04/2018
NCPE assessment outcome The NCPE recommends that eliglustat (Cerdelga®) should not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*

*This recommendation should be considered while also having regard to the criteria as specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations September 2018